- Home
- KUKE vs OCEA Comparison
KUKE vs OCEA Comparison
Compare KUKE & OCEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KUKE
- OCEA
- Stock Information
- Founded
- KUKE 2002
- OCEA 2019
- Country
- KUKE China
- OCEA United States
- Employees
- KUKE N/A
- OCEA N/A
- Industry
- KUKE Other Consumer Services
- OCEA Biotechnology: Pharmaceutical Preparations
- Sector
- KUKE Real Estate
- OCEA Health Care
- Exchange
- KUKE Nasdaq
- OCEA Nasdaq
- Market Cap
- KUKE 18.9M
- OCEA 20.5M
- IPO Year
- KUKE 2021
- OCEA N/A
- Fundamental
- Price
- KUKE $0.31
- OCEA $0.13
- Analyst Decision
- KUKE
- OCEA
- Analyst Count
- KUKE 0
- OCEA 0
- Target Price
- KUKE N/A
- OCEA N/A
- AVG Volume (30 Days)
- KUKE 126.0K
- OCEA 88.9M
- Earning Date
- KUKE 04-15-2025
- OCEA 01-13-2025
- Dividend Yield
- KUKE N/A
- OCEA N/A
- EPS Growth
- KUKE N/A
- OCEA N/A
- EPS
- KUKE N/A
- OCEA N/A
- Revenue
- KUKE $14,784,158.00
- OCEA N/A
- Revenue This Year
- KUKE N/A
- OCEA N/A
- Revenue Next Year
- KUKE N/A
- OCEA N/A
- P/E Ratio
- KUKE N/A
- OCEA N/A
- Revenue Growth
- KUKE 10.48
- OCEA N/A
- 52 Week Low
- KUKE $0.23
- OCEA $0.11
- 52 Week High
- KUKE $4.07
- OCEA $7.79
- Technical
- Relative Strength Index (RSI)
- KUKE 34.52
- OCEA 28.02
- Support Level
- KUKE $0.36
- OCEA $0.12
- Resistance Level
- KUKE $0.50
- OCEA $0.16
- Average True Range (ATR)
- KUKE 0.06
- OCEA 0.04
- MACD
- KUKE -0.01
- OCEA 0.01
- Stochastic Oscillator
- KUKE 4.92
- OCEA 8.66
About KUKE Kuke Music Holding Limited
Kuke Music Holding Ltd provides classical music licensing, subscription, and education services in China. The company licenses its music content to online music entertainment platforms, such as Tencent Music Entertainment Group, digital music service providers, such as NetEase Cloud Music, as well as film and TV production companies, airlines, and smart hardware companies. Users can access the platform through the website, mobile app, and smart music devices.
About OCEA Ocean Biomedical Inc.
Ocean Biomedical Inc is a biopharmaceutical company that is focused on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases. The company is developing an antibody therapeutic product candidate inhibiting Chi3l1, and a bi-specific antibody product candidate inhibiting Chi3l1 plus PD-1 and CTLA-4 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome.